JSH-23

JSH-23 is an inhibitor of NF-κB, blocking its translocation into the nucleus (IC₅₀ = 7.1 µM).¹ It does not affect degradation of the inhibitor of NF-κB, IκB.¹ JSH-23 interferes with NF-κB-mediated gene expression and apoptosis in RAW 264.7 cells treated with lipopolysaccharide.¹ It has also been used to investigate the roles of NF-κB in cancer, inflammation, and neurogenesis.^2,3,4

WARNING This product is not for human or veterinary use.

1. Shin, H.M., Kim, M.H., Kim, B.H., et al. Inhibitory action of novel aromatic diamine compound on lipopolysaccharide-induced nuclear translocation of NF-κB without affecting IκB degradation. FEBS Lett. 571(1-3), 50-54 (2004).

2. Ahmed, K.M., Zhang, H., and Park, C.C. NF-κB regulates radioresistance mediated by β1-integrin in three-dimensional culture of breast cancer cells. Cancer Res. 73(12), 3737-3748 (2013).

3. Kumar, A., Negi, G., and Sharma, S.S. JSH-23 targets nuclear factor-kappa B and reverses various deficits in experimental diabetic neuropathy: Effect on neuroinflammation and antioxidant defence. Diabetes Obes. Metab. 13(8), 750-758 (2011).

4. Koo, J.W., Russo, S.J., Ferguson, D., et al. Nuclear factor-κB is a critical mediator of stress-impaired neurogenesis and depressive behavior. Proc. Natl. Acad. Sci. USA 107(6), 2669-2674 (2010).

Kumar, R., Bhat, T.A., Walsh, E.M., et al. Cytochrome c deficiency confers apoptosome and mitochondrial dysfunction in African-American men with prostate cancer. Cancer Res. 79(7), 1353-1368 (2019).